PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of westjmedLink to Publisher's site
 
West J Med. 1998 February; 168(2): 114–120.
PMCID: PMC1304839

Practical guidelines for the treatment of malignant gliomas.

Abstract

The treatment of patients with malignant gliomas is palliative and encompasses surgery, radiotherapy, and chemotherapy. Outcome measures have demonstrated improvement in both survival and neurologic performance in patients undergoing complete or near-complete tumor resection. After surgery, involved-field radiotherapy (radiotherapy administered to the tumor and to the tissue in a 3-cm radius surrounding the tumor) has been shown to further improve survival rates when given in a total dose of 6000-6500 cGy. Survival is further improved by the coadministration of the chemoradiopotentiator hydroxycarbamide (hydroxyurea). The role of adjuvant or boost stereotactic radiotherapy is unclear, despite its frequent use. In addition, adjuvant chemotherapy has been shown to improve survival rates in approximately one-quarter of patients with glioblastoma multiforme and in the majority of patients with anaplastic astrocytoma. No a priori method exists, however, to predict which patient will benefit from adjuvant chemotherapy. As a consequence, all physiological young patients with good performance status or limited neurologic disability are treated with chemotherapy. The best results of adjuvant chemotherapy are achieved with a nitrosourea chemotherapy, either carmustine (BCNU) or a combination of procarbazine and lomustine (CCNU) and vincristine, known as PCV-3 therapy. Salvage chemotherapy is reserved for patients with tumor progression, some of whom benefit from a re-operation. Occasional patients with recurrent gliomas may be palliated by stereotactic radiotherapy.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Black PM. Brain tumors. Part 1. N Engl J Med. 1991 May 23;324(21):1471–1476. [PubMed]
  • Black PM. Brain tumor. Part 2. N Engl J Med. 1991 May 30;324(22):1555–1564. [PubMed]
  • Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology. 1985 Feb;35(2):219–226. [PubMed]
  • Mahaley MS, Jr, Mettlin C, Natarajan N, Laws ER, Jr, Peace BB. National survey of patterns of care for brain-tumor patients. J Neurosurg. 1989 Dec;71(6):826–836. [PubMed]
  • Riggs JE. Rising primary malignant brain tumor mortality in the elderly. A manifestation of differential survival. Arch Neurol. 1995 Jun;52(6):571–575. [PubMed]
  • Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, Sanford RA, Mulhern RK, James HE, Freeman CR, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993 Jun 17;328(24):1725–1731. [PubMed]
  • Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993 Sep;43(9):1678–1683. [PubMed]
  • Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L. Age influences chemotherapy response in astrocytomas. Neurology. 1995 May;45(5):929–933. [PubMed]
  • Kuratsu J, Ushio Y. Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto Prefecture in the southern part of Japan. J Neurosurg. 1996 Jun;84(6):946–950. [PubMed]
  • Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery. 1987 Aug;21(2):201–206. [PubMed]
  • Barker FG, 2nd, Prados MD, Chang SM, Gutin PH, Lamborn KR, Larson DA, Malec MK, McDermott MW, Sneed PK, Wara WM, et al. Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg. 1996 Mar;84(3):442–448. [PubMed]
  • Shapiro WR, Green SB, Burger PC, Mahaley MS, Jr, Selker RG, VanGilder JC, Robertson JT, Ransohoff J, Mealey J, Jr, Strike TA, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989 Jul;71(1):1–9. [PubMed]
  • Halperin EC, Burger PC. Conventional external beam radiotherapy for central nervous system malignancies. Neurol Clin. 1985 Nov;3(4):867–882. [PubMed]
  • Florell RC, Macdonald DR, Irish WD, Bernstein M, Leibel SA, Gutin PH, Cairncross JG. Selection bias, survival, and brachytherapy for glioma. J Neurosurg. 1992 Feb;76(2):179–183. [PubMed]
  • Levin VA. Chemotherapy of primary brain tumors. Neurol Clin. 1985 Nov;3(4):855–866. [PubMed]
  • Kornblith PL, Walker M. Chemotherapy for malignant gliomas. J Neurosurg. 1988 Jan;68(1):1–17. [PubMed]
  • Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321–324. [PubMed]
  • Stewart DJ. The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat Rev. 1989 Sep;16(3):129–160. [PubMed]
  • Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol. 1992 May;10(5):766–771. [PubMed]
  • Longee DC, Friedman HS, Albright RE, Jr, Burger PC, Oakes WJ, Moore JO, Schold SC., Jr Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg. 1990 Apr;72(4):583–588. [PubMed]
  • Newton HB, Junck L, Bromberg J, Page MA, Greenberg HS. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology. 1990 Nov;40(11):1743–1746. [PubMed]
  • Spence AM, Berger MS, Livingston RB, Ali-Osman F, Griffin B. Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J Neurooncol. 1992 Feb;12(2):187–191. [PubMed]
  • Fadul C, Wood J, Thaler H, Galicich J, Patterson RH, Jr, Posner JB. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology. 1988 Sep;38(9):1374–1379. [PubMed]
  • Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990 Jul;8(7):1277–1280. [PubMed]

Articles from The Western Journal of Medicine are provided here courtesy of BMJ Group